latest news releases from the newsroom
NXP Membership in MoCA Expands Worldwide Presence of Alliance
SAN RAMON, Calif., July 10, 2007 (PRIME NEWSWIRE) -- NXP Semiconductors has joined MoCA(tm) as its newest IC vendor member. NXP is an independent semiconductor company, founded by Philips more than 50 years ago. The company is a recognized leader in numerous system-on-chip experiences, providing semiconductors and system solutions for a wide range of applications, ranging from mobile to home and automotive to identification.
COSCO ESP Inc.
COSCO Continues to Seek Equity and Debt Financing
EDMONTON, Alberta, July 10, 2007 (PRIME NEWSWIRE) -- Mr. Mark Dorin, President & Director of COSCO ESP Inc., (Pink Sheets:CCPI), ("COSCO") or (the "Company"), would like to announce that the Company continues to actively seek equity investment and debt financing to fund existing orders. In the past six months progress has been made in these attempts; however, COSCO has yet to secure the complete financing required to fulfill its order financing and working capital requirements. This information is being provided to shareholders as an update to those who have participated and those that are yet to participate in any financing opportunities with COSCO.
Vostok New Ventures Ltd.
Vostok Nafta: NET ASSET VALUE OF VOSTOK NAFTA INVESTMENT LTD AS OF JUNE 29, 2007
Net asset value per share: USD: 12.15, SEK: 83.02
Change in net asset value (USD/share) June 2007: 53.60%
Change in net asset value (USD/share) June 2007, excluding anticipated proceeds
from new share issue: 13.81%
RTS index development, June 2007: 6.59%
Three largest holdings, June 29, 2007 (Share of stockholdings):
1. Black Earth Farming 23.05%
2. TNK BP Holding Pref 16.76%
3. Belon 7.44%
Vostok Nafta’s estimated net asset value as of June 29, 2007 amounted to appro
Samaritan Pharmaceuticals, Inc.
Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease
LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce it has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in-vitro data and suggests Caprospinol may not only slow down Alzheimer's but may also reverse plaque-related brain injuries associated with the mind-robbing disease of Alzheimer's.